SCHEMBL6895562

SCHEMBL6895562

C#Cc1ccc(S(=O)(=O)N2CCN(CC3CCNCC3)C(=O)C2)cc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.37
DRD2 P14416 1/20 0.36
MAPT P10636 1/20 0.35
HTR6 P50406 3/20 0.35
CYP19A1 P11511 1/20 0.34
KDM1A O60341 1/20 0.34
PARP1 P09874 1/20 0.33
F2 P00734 1/20 0.33
F10 P00742 1/20 0.33
NAMPT P43490 1/20 0.33
EPHX2 P34913 1/20 0.33
GFER P55789 1/20 0.33
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CNR2 P34972 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6894706 0.83 LSS (0.46) CYP19A1F10NAMPTSMN1; SMN2
Hydrochloric Acid SCHEMBL6893869 0.82 LSS (0.45) HTR6CYP19A1F10NAMPTSMN1; SMN2
Hydrochloric Acid SCHEMBL6893032 0.77 DRD2 (0.45) PKMDRD2MAPTHTR6F2
Hydrochloric Acid SCHEMBL6891778 0.76 CYP19A1 (0.43) CYP19A1
Hydrochloric Acid SCHEMBL6891758 0.76 CYP19A1 (0.43) CYP19A1
SCHEMBL6893878 0.72 LSS (0.44) HTR6F10SMN1; SMN2
Hydrochloric Acid SCHEMBL7056386 0.72 DRD2 (0.41) PKMDRD2HTR6F2F10
Hydrochloric Acid SCHEMBL6895872 0.71 LSS (0.43) HTR6F10SMN1; SMN2
SCHEMBL1386651 0.69 F10 (0.59) F2F10
Hydrochloric Acid SCHEMBL6896345 0.69 F10 (0.42) DRD2F2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6680312-B2 FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2004-01-20 US disclosed
US-20020193382-A1 Sulfonamide derivatives, their production and use TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) 2002-12-19 US disclosed
US-6403595-B1 ANTICOAGULANTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2002-06-11 US disclosed
EP-1054005-A1 SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF Takeda Chemical Industries, Ltd. (JP) 2000-11-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193382-A1 Sulfonamide derivatives, their production and use F12, F11, F2 PKM 2642/4885DRD2 1934/4885MAPT 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.